Received: 9 October 2019
Accepted: 24 April 2020
First Online: 14 May 2020
Ethics approval and consent to participate
: The study was approved by the Ethics Committee “Nordrhein.” It is registered with respect to clinicaltrials.gov as “NCT01049425.”
: Not applicable
: Fred Heinisch, Matthias Christgen, Toralf Reimer, Friedrich Feuerhake, Michael Clemens Monika Graeser, and Ronald Kates have reported no potential conflict of interest.Cornelia Kolberg-Liedtke has received honoraria/travel support by Phaon Scientific, Novartis, Pfizer, Celgene, Roche, AstraZeneca, Lilly, HEXAL, Amgen, Eisai, and SonoScape and has received research funding by Roche, Novartis, and Pfizer (CKL). Rachel Würstlein has reported financial support by Agendia, Amgen, Aristo, Astra Zeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnolgogy, Riemser, Roche, Seattle Genetics, Tesaro Bio, and Teva. Hans Kreipe has received honoraria from AstraZeneca, Genomic Health, Roche Pharma, Novartis, Amgen, and Pfizer. Wolfram Malter has received honoraria from Genomic Health, Pfizer, Novartis, NanoString, Celgene, and Roche. Oleg Gluz has reported personal fees/travel support from Genomic Health, NanoString Technologies, Roche, Celgene, and Teva.Benno Nuding has served in a consulting or advisory role for Roche, Novartis, and Pfizer. Steven Shak is an employee and stock owner for Genomic Health. Ulrike Nitz has received personal fees from Genomic Health and Roche. Nadia Harbeck has received honoraria for lectures and consulting from Daiichi-Sankyo, Novartis, and Roche.